Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Aug 21, 2009; 15(31): 3855-3864
Published online Aug 21, 2009. doi: 10.3748/wjg.15.3855
Published online Aug 21, 2009. doi: 10.3748/wjg.15.3855
Table 2 Outcomes related to secondary hepatic resection in patients treated with irinotecan-based chemotherapy
| Study | n | Regimen | Response rate (%) | Resection rate (%) | R0 rate (%) | MS (mo) |
| Unselected populations | ||||||
| Tournigand et al[14] | 109 | FOLFIRI | 61.0 | 9.0 | 7.0 | 47 |
| Colucci et al[23] | 178 | FOLFIRI | 36.0 | 5.1 | NR | NR |
| Liver metastases only | ||||||
| Pozzo et al[26] | 40 | 5-FU/LV, irinotecan | 47.5 | 40.0 | 32.5 | NYR |
| Zelek et al[27] | 31 | 5-FU/LV, irinotecan, and HAI of pirarubicin | 48.0 | 35.0 | 29.0 | NYR |
| Ho et al[28] | 40 | 5-FU/LV, irinotecan | 55.0 | 10.0 | NR | NR |
- Citation: Saif MW. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol 2009; 15(31): 3855-3864
- URL: https://www.wjgnet.com/1007-9327/full/v15/i31/3855.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.3855